Status:
UNKNOWN
CTFEA Myeloma Study
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Collaborating Sponsors:
Tel Aviv University
Conditions:
Myeloma Multiple
Metastatic Bone Tumor
Eligibility:
All Genders
18-95 years
Brief Summary
Patients with Multiple Myeloma are monitored for disease progression and for response to treatment by the treating hematologist or oncologist. Laboratory tests are usually utilized for these purposes....
Detailed Description
Background Multiple myeloma (MM) is the most common primary bone malignancy, caused by proliferation of plasma cells secreting immunoglobulins. Active MM (aMM) is characterized in many patients by mu...
Eligibility Criteria
Inclusion
- All patients with Active Multiple Myeloma
Exclusion
- Inability to provide informed consent or lack of consent.
- Inadequate CT scans
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04364724
Start Date
June 1 2020
End Date
March 31 2024
Last Update
April 28 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.